NCT00111098View on ClinicalTrials.gov

Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis

PHASE3CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions

Kidney Disease

Interventions

DRUG

Darbepoetin Alfa

QM administration for 28 weeks, adjusted as necessary to maintain Hb between 11.0 - 13.0 g/dL PFS concentrations: 20, 30, 40, 50, 60, 80, 100, 150, 200 and 300 mcg.